Alzheimer's disease research
Alzheimer's disease (AD) is a debilitating disease characterized by progressive dementia and the accumulation of amyloid-beta and tau proteins into plaques and neurofibrillary tangles in the brain. While it affects ~5.8 million adults and is the sixth leading cause of death in the USA, no disease-modifying therapy has been found and its underlying molecular architecture remains poorly understood. Our struggle against AD has been profoundly challenging, but we have learned much over the century since its discovery. There are currently over 400 clinical trials underway, representing a multipronged approach investigating the possibility of immunotherapy, our microbiome, and inflammation as prospective therapeutic targets. But with these new approaches come new experimental obstacles and a growing need for sensitive, reproducible, and high-throughput technologies to expedite our understanding.
Fortunately, we're up to the challenge. See how our best-in-class solutions can help advance your AD research.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2022 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.